Cariprazine, an original antipsychotic drug developed by Hungarian pharmaceutical company Gedeon Richter Plc. is available in 64 countries and has become a multiple blockbuster in the US, with sales of nearly $3 billion. It is a unique achievement that a Hungarian drug candidate – discovered and developed locally – has been granted FDA and EU approvals, and the company already has several further molecules in its pipeline. „Thousands of psychiatrists arrived to Budapest for the European Congress of Psychiatry, and perhaps even they are unaware of how important role Hungarian researchers have played in this field worldwide. We have nearly 1200 researchers, making us the largest innovation base in the whole region. The fact that cariprazine has been among the TOP 100 drugs by sales for several years now is an outstanding achievement comparable to winning an Olympic medal,“ Gábor Orbán, CEO of Richter said… 

MEDSIR, a leading company dedicated to the strategic design of independent clinical research, participated in the Annual Meeting of the American Association for Cancer Research, a premier event that brings together scientists, clinicians, industry professionals, advocates, and other stakeholders in the field of cancer research, presenting the results of two sub-studies focused on biomarkers: transFal, focused on patients with HR+/HER2- advanced breast cancer and METSGain, centered on patients with early breast cancer. Both studies underscore the importance of utilizing biomarkers. Their early detection has been shown to increase patient survival rates by aiding in selecting the most appropriate treatment for patients. In the context of personalized medicine, biomarkers are also important for tailoring treatments for individual patients based on their unique biological characteristics, allowing for more precise and effective medical interventions. These findings represent significant strides in understanding and leveraging…